Gestational weight gain in women with type 1 and type 2 diabetes mellitus is related to both general and diabetes-related clinical characteristics

Xie, Xinglei; Liu, Jiaming; García-Patterson, Apolonia; Chico, Ana; Mateu-Salat, Manel; Amigó, Judit; Adelantado, Juan María; Corcoy, Rosa

doi:10.1007/s42000-023-00497-9

Cited by 5 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More intensive insulin therapy, introduced during pregnancy, is also associated with greater weight gain compared to the standard dosage [ 27 ]. Of the 633 women with T1DM and type 2 diabetes mellitus (T2DM) studied by Xie et al [ 29 ], 42.5% had EGWG. Among the predictors of EGWG, the authors pointed to height, pre-pregnancy BMI, multiple pregnancies, and pump use and insulin dose in the third trimester.…”

Section: Pathophysiology and Risk Factors Of Egwgmentioning

confidence: 99%

Recent Insights and Recommendations for Preventing Excessive Gestational Weight Gain

Niebrzydowska-Tatus,

Pełech,

Rekowska

et al. 2024

JCM

View full text Add to dashboard Cite

Recommendations for weight gain during pregnancy are based on pre-pregnancy body mass index (BMI). Pregnancy is a risk factor for excessive weight gain and many endocrine problems, making it difficult to return to pre-pregnancy weight and increasing the risk of postpartum obesity and, consequently, type 2 diabetes and metabolic syndrome. Both excessive gestational weight gain (EGWG) and obesity are associated with an increased risk of gestational hypertension, pre-eclampsia, gestational diabetes, cesarean section, shoulder dystocia, and neonatal macrosomia. In the long term, EGWG is associated with increased morbidity and mortality, particularly from diabetes, cardiovascular disorders, and some cancers. This study aims to present recommendations from various societies regarding weight gain during pregnancy, dietary guidance, and physical activity. In addition, we discuss the pathophysiology of this complication and the differential diagnosis in pregnant women with EGWG. According to our research, inadequate nutrition might contribute more significantly to the development of EGWG than insufficient physical activity levels in pregnant women. Telehealth systems seem to be a promising direction for future EGWG prevention by motivating women to exercise. Although the importance of adequate pre-pregnancy weight and weight gain during pregnancy is well known, an increasing number of women gain excessive weight during pregnancy.

show abstract

Section: Pathophysiology and Risk Factors Of Egwgmentioning

confidence: 99%

Recent Insights and Recommendations for Preventing Excessive Gestational Weight Gain

Niebrzydowska-Tatus,

Pełech,

Rekowska

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

Technology advances in diabetes pregnancy: right technology, right person, right time

McLean,

Maple-Brown,

Murphy

2024

Diabetologia

View full text Add to dashboard Cite

This review outlines some of the extraordinary recent advances in diabetes technology, which are transforming the management of type 1 diabetes before, during and after pregnancy. It highlights recent improvements associated with use of continuous glucose monitoring (CGM) but acknowledges that neither CGM nor insulin pump therapy are adequate for achieving the pregnancy glucose targets. Furthermore, even hybrid closed-loop (HCL) systems that are clinically effective outside of pregnancy may not confer additional benefits throughout pregnancy. To date, there is only one HCL system, the CamAPS FX, with a strong evidence base for use during pregnancy, suggesting that the pregnancy benefits are HCL system specific. This is in stark contrast to HCL system use outside of pregnancy, where benefits are HCL category specific. The CamAPS FX HCL system has a rapidly adaptive algorithm and lower glucose targets with benefits across all maternal glucose categories, meaning that it is applicable for all women with type 1 diabetes, before and during pregnancy. For women of reproductive years living with type 2 diabetes, the relative merits of using non-insulin pharmacotherapies vs diabetes technology (dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists and sodium−glucose cotransporter 2 inhibitors) are unknown. Despite the urgent unmet need and potential benefits, studies of pharmacotherapy and technology use are extremely limited in pregnant women with type 2 diabetes. Graphical Abstract

show abstract

Genetics of primary hyperparathyroidism, our first Batrinos’ scholar review, metabolic syndrome, and quite a bit of reproductive endocrinology: a great issue

Stratakis

2024

Hormones

View full text Add to dashboard Cite

Gestational weight gain in women with type 1 and type 2 diabetes mellitus is related to both general and diabetes-related clinical characteristics

Cited by 5 publications

References 34 publications

Recent Insights and Recommendations for Preventing Excessive Gestational Weight Gain

Recent Insights and Recommendations for Preventing Excessive Gestational Weight Gain

Technology advances in diabetes pregnancy: right technology, right person, right time

Genetics of primary hyperparathyroidism, our first Batrinos’ scholar review, metabolic syndrome, and quite a bit of reproductive endocrinology: a great issue

Contact Info

Product

Resources

About